Aptose Biosciences - APTO Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APTO shares.
View APTO analyst ratings or view top-rated stocks.

4 brokerages have issued 12-month price objectives for Aptose Biosciences' stock. Their APTO share price forecasts range from $5.00 to $12.00. On average, they anticipate the company's stock price to reach $7.75 in the next twelve months. This suggests a possible upside of 1,043.1% from the stock's current price.
View analysts price targets for APTO or view top-rated stocks among Wall Street analysts.

Aptose Biosciences' stock was trading at $1.35 on January 1st, 2022. Since then, APTO stock has decreased by 49.8% and is now trading at $0.6780.
View the best growth stocks for 2022 here.

Aptose Biosciences saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 692,100 shares, an increase of 163.7% from the October 31st total of 262,500 shares. Based on an average daily volume of 356,000 shares, the days-to-cover ratio is currently 1.9 days.
View Aptose Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our APTO earnings forecast.

Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings data on Thursday, November, 11th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same period last year, the company earned ($0.15) EPS.

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Aptose Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (7.46%), Carlson Capital L P (2.18%), Sigma Planning Corp (0.97%), Annandale Capital LLC (0.77%), Sanders Morris Harris LLC (0.71%) and Voss Capital LLC (0.65%). Insiders that own company stock include Denis R Burger, Donald R Jr Wilson, Erich Platzer, Gregory K Chow, Jotin Marango, Rafael Bejar, Warren Whitehead and William G Rice.
View institutional ownership trends.

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APTO stock can currently be purchased for approximately $0.68.

Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $62.57 million. The biotechnology company earns $-65,350,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120.